Discussion

Open Access

Discussion

Session: Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl

Topic: Lipid-Lowering Agents

Speaker: Professor P. Libby (Boston, US) Professor E. Stroes (Amsterdam, NL) Professor P. Steg (Paris, FR) Doctor P. Taub (La Jolla, US)

Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amarin

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speakers

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)

37 presentations

7 followers

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))

39 presentations

0 follower

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

66 presentations

10 followers

Doctor Pam Taub

University of California San Diego, La Jolla (United States of America)

6 presentations

1 follower

4 more presentations in this session

Introduction

Speaker: Professor P. Libby (Boston, US)

Access

Slides

Video

Challenges in atherosclerotic cardiovascular disease reduction and triglyceride-related risk

Speaker: Professor E. Stroes (Amsterdam, NL)

Access

Slides

Video

Perspectives on the results of recent clinical outcome trials with icosapent ethyl

Speaker: Professor P. Steg (Paris, FR)

Access

Slides

Video

Integrating icosapent ethyl in cardiovascular risk reduction strategies: practical guidance

Speaker: Doctor P. Taub (La Jolla, US)

Access

Slides

Video

Access the full session

Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl

Speakers: Professor P. Libby, Professor E. Stroes, Professor P. Steg, Doctor P. Taub, Professor P. Libby...

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources